Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Durata Therapeutics, Inc.

http://www.duratatherapeutics.com/

Latest From Durata Therapeutics, Inc.

Roche’s Alzheimer’s Drug Fails In Phase III Giving Eisai/Biogen A Clear Run

Roche’s gantenerumab has failed to make the grade in its GRADUATE studies, leaving the field wide open for Eisai and Biogen’s lecanemab.

Clinical Trials Companies

Vabysmo Is Bright Spot For Roche In Bumpy Q3

Roche's pharma revenues declined in the third quarter, but the Swiss major is hoping that Tecentriq in adjuvant settings can boost future revenues – and that, just maybe, it will have a win from its Alzheimer’s candidate too.

Sales & Earnings Companies

Happify Health Collaborates With Biogen To Support People Living With Multiple Sclerosis

Biogen and Happy Health announced a pilot partnership to evaluate Happify Health’s Kopa app to support people living with multiple sclerosis. This follows a licensing deal with digital therapeutics developer MedRhythms to support MS patients with gait deficit.

Digital Health Deals

Failure Of Roche’s Nine-Year Alzheimer’s Prevention Study Disappointing, But No Surprise

The ambitious prevention study in people with a nearly 100% chance of developing Alzheimer’s disease has failed, and attention will now switch to trial readouts for the next generation of beta-amyloid targeting candidates.

Neurology Clinical Trials
See All

Company Information

UsernamePublicRestriction

Register